These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 32977745)
1. HIV prevention is not all about HIV - using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. Vickerman P; Quaife M; Kilbourne-Brook M; Mvundura M; Eakle R; Terris-Prestholt F BMC Infect Dis; 2020 Sep; 20(1):704. PubMed ID: 32977745 [TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654 [TBL] [Abstract][Full Text] [Related]
3. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa. Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Kilbourne-Brook M; Mvundura M; Delany-Moretlwe S; Terris-Prestholt F Med Decis Making; 2018 Jan; 38(1):120-133. PubMed ID: 28863752 [TBL] [Abstract][Full Text] [Related]
4. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). Ngure K; Friedland BA; Szydlo DW; Roberts ST; Garcia M; Levy L; Akello CA; Reddy K; Palanee-Phillips T; Macdonald P; Siziba B; Soto-Torres L; Hosek S; Hillier SL; Nair G; Celum C; van der Straten A PLoS One; 2023; 18(6):e0287525. PubMed ID: 37352296 [TBL] [Abstract][Full Text] [Related]
5. Preferences for Long-Acting PrEP Products Among Women and Girls: A Quantitative Survey and Discrete Choice Experiment in Eswatini, Kenya, and South Africa. Little KM; Hanif H; Anderson SM; Clark MR; Gustafson K; Doncel GF AIDS Behav; 2024 Mar; 28(3):936-950. PubMed ID: 37971614 [TBL] [Abstract][Full Text] [Related]
6. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323 [TBL] [Abstract][Full Text] [Related]
7. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040 [TBL] [Abstract][Full Text] [Related]
8. Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment. Quaife M; Eakle R; Cabrera M; Vickerman P; Tsepe M; Cianci F; Delany-Moretlwe S; Terris-Prestholt F BMJ Open; 2016 Jun; 6(6):e010682. PubMed ID: 27354071 [TBL] [Abstract][Full Text] [Related]
9. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. van der Straten A; Ryan JH; Reddy K; Etima J; Taulo F; Mutero P; Taylor J; Piper J; Musara P; J Int AIDS Soc; 2020 Jun; 23(6):e25536. PubMed ID: 32524700 [TBL] [Abstract][Full Text] [Related]
10. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study. Mack N; Evens EM; Tolley EE; Brelsford K; Mackenzie C; Milford C; Smit JA; Kimani J J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616 [TBL] [Abstract][Full Text] [Related]
11. HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa. Little KM; Flomen L; Hanif H; Anderson SM; Thurman AR; Clark MR; Doncel GF AIDS Behav; 2022 Sep; 26(9):3099-3109. PubMed ID: 35360893 [TBL] [Abstract][Full Text] [Related]
12. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa. Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697 [TBL] [Abstract][Full Text] [Related]
13. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe. Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746 [TBL] [Abstract][Full Text] [Related]
14. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936 [TBL] [Abstract][Full Text] [Related]
15. Acceptability and Predictors of Uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) Among Fishing Communities in Uganda: A Cross-Sectional Discrete Choice Experiment Survey. Kuteesa MO; Quaife M; Biraro S; Katumba KR; Seeley J; Kamali A; Nakanjako D AIDS Behav; 2019 Oct; 23(10):2674-2686. PubMed ID: 30734882 [TBL] [Abstract][Full Text] [Related]
16. Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe. Young AM; Stoner MCD; Mathebula F; Mohuba R; Baez A; Seyama L; Mutero P; Etima J; Fabiano Z; Fairlie L; Mayo AJ; Balkus JE; Song M; Bunge K; Piper J; Balan IC; van der Straten A; Montgomery ET AIDS Behav; 2024 Nov; 28(11):3615-3628. PubMed ID: 39052199 [TBL] [Abstract][Full Text] [Related]
17. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa. Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785 [TBL] [Abstract][Full Text] [Related]
18. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study. Mayanja Y; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Buzibye A; Omali D; Chinyenze K; Kuteesa M; Kaleebu P; Price MA J Int AIDS Soc; 2022 May; 25(5):e25909. PubMed ID: 35543110 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240 [TBL] [Abstract][Full Text] [Related]
20. An individually randomized controlled trial of a mother-daughter HIV/STI prevention program for adolescent girls and young women in South Africa: IMARA-SA study protocol. Donenberg GR; Atujuna M; Merrill KG; Emerson E; Ndwayana S; Blachman-Demner D; Bekker LG BMC Public Health; 2021 Sep; 21(1):1708. PubMed ID: 34544403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]